Coagulation Parameters With Albumin in Decompensated Cirrhosis (CoPA-D).
Key facts
- Who runs it
- Institute of Liver and Biliary Sciences, India
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 120 people enrolled
- Started
- 30 Jul 2023
- Ended
- 25 Nov 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Albumin
- Standard of Care
- Record updated
- 4 June 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Age ≥ 18 years and ≤ 70 years
- Decompensated cirrhosis of any cause
- S. Albumin ≤ 2.5 g/dl upon presentation
- Written informed consent
Who cannot take part
- Post liver transplant patients
- Known or suspected cardiac dysfunction
- Severe psychiatric disorders
- Patients admitted with proven indications for albumin (SBP, HRS, LVP)
- Albumin infusion within the past 3 weeks
- Patients of ACLF
- Advanced HCC
- Presence of hypotension
- PF ratios ≤ 300 mmHg on arterial blood gas
- IVC Collapsibility Index < 20%
- AKI or CKD
- Acute GI Bleed
- Severe Anemia
- Pregnant women
- PLHA
- Lack of informed consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Albumin is commonly used plasma expander in patients of decompensated cirrhosis and has been found to have many beneficial effects, with few studies showing that maintenance of serum albumin levels above 3 g/dl has improved outcomes and mortality leading to widespread utilization in patients with cirrhosis of the liver.
Read full original descriptionShow less
While 20% human albumin solution has been subject to in-depth analysis along several fronts, it's effects on coagulation parameters is unknown. With cirrhosis being a state of dysregulated clotting and bleeding, it is imperative to know the effects of such a widely used plasma expander on coagulation.
The aim of this study is to evaluate the effects of albumin on coagulation parameters in patients of decompensated cirrhosis.
The 2 groups in the trial
- AlbuminTreatment being tested
20% human albumin solution infusion, to raise and maintain serum albumin levels above 3.0 g/dl. Human albumin solution will be given to those enrolled in the study having serum albumin levels ≤ 3 g/dl to maintain the serum albumin levels above 3 g/dl.
- Standard of CareExisting treatment, for comparison
Standard treatment that the patient would receive had they not been included in the trial.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Coagulation Parameters With Albumin in Decompensated Cirrhosis (CoPA-D): An Open-label Randomized Control Trial
- Record updated
- 4 June 2025